Moreover, the results obtained here represent a scenario of severe T1DM (i.e., BG ≥300 gm/dL) and may not be generalizable to patients under insulin therapy, although a clinical study reported reduced bone mass in young subjects with moderate T1DM who had good metabolic control 32. The gene discussed is INS; the disease is type 1 diabetes mellitus.